Among MET-positive patients , higher rilotumumab exposure , vs placebo and low exposure , was associated with improved median PFS ( @ % CI : @ ( @-@ @ ) vs @ ( @-@ @ ) and @ ( @-@ @ ) months ) and OS ( @ ( @-@ @ ) vs @ ( @-@ @ ) and @ ( @-@ @ ) months ) without increased toxicity .